Viela Bio, Inc. Contracts & Agreements
36 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (5)
- Human Resources (10)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (1)
- Uncategorized (9)
- Consulting Agreement by and between Horizon Therapeutics USA, Inc. and Zhengbin (Bing) Yao, Ph.D., dated as of February 27, 2021 (Filed With SEC on March 4, 2021)
- Agreement and Plan of Merger, dated January 31, 2021, by and among Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc., Viela Bio, Inc. and solely for purposes of Sections... (Filed With SEC on February 1, 2021)
- Form of Tender and Support Agreement (Filed With SEC on February 1, 2021)
- Form of Underwriting Agreement (Filed With SEC on May 26, 2020)
- Description of Securities (Filed With SEC on March 25, 2020)
- Non-Employee Director Compensation Plan (Filed With SEC on March 25, 2020)
- License Agreement by and between the Company and Mitsubishi Tanabe Pharma Corporation, dated October 8, 2019 (Filed With SEC on March 25, 2020)
- Form of Underwriting Agreement (Filed With SEC on September 23, 2019)
- Form of Common Stock Certificate (Filed With SEC on September 23, 2019)
- Amended and Restated 2018 Equity Incentive Plan, and forms of award agreements thereunder (Filed With SEC on September 23, 2019)
- Amended and Restated Investors Rights Agreement, by and between the Registrant and the stockholders of the Registrant listed therein, dated June 12, 2019 (Filed With SEC on August 29, 2019)
- Form of Indemnification Agreement (Filed With SEC on August 29, 2019)
- Amended and Restated 2018 Equity Incentive Plan, and forms of award agreements thereunder (Filed With SEC on August 29, 2019)
- Employment Agreement, by and between the Registrant and Zhengbin (Bing) Yao, Ph.D., dated August 28, 2019 (Filed With SEC on August 29, 2019)
- Employment Agreement, by and between the Registrant and Jrn Drappa, Ph.D., dated August 28, 2019 (Filed With SEC on August 29, 2019)
- Employment Agreement, by and between the Registrant and Aaron Ren, Ph.D., dated August 28, 2019 (Filed With SEC on August 29, 2019)
- Offer Letter, by and between the Registrant and Mitchell Chan, dated August 15, 2018 (Filed With SEC on August 29, 2019)
- Offer Letter, by and between the Registrant and William Ragatz, dated November 27, 2018 (Filed With SEC on August 29, 2019)
- License Agreement, by and between Duke University and Cellective Therapeutics, Inc., dated September 21, 2004 as amended by the Letter Agreement dated September 9, 2005 (assigned... (Filed With SEC on August 29, 2019)
- License Agreement by and between Dana-Farber Cancer Institute, Inc. and Cellective Therapeutics, Inc., as amended, dated December 21, 2004 as amended by the Letter Agreement dated... (Filed With SEC on August 29, 2019)
- BioWa Sublicense Agreement, by and between the Registrant and MedImmune, LLC, dated as of February 23, 2018 (Filed With SEC on August 29, 2019)
- License Agreement between SBI Biotech Co. Ltd. and MedImmune, LLC, dated as of September 9, 2008 (assigned to the Registrant pursuant to the Asset Purchase Agreement by and... (Filed With SEC on August 29, 2019)
- Supplemental Agreement dated as of August 14, 2018, by and between SBI Biotech Co. Ltd. and the Registrant (Filed With SEC on August 29, 2019)
- BioWa/Lonza Sublicense Agreement, by and between the Registrant and MedImmune, LLC, dated as of February 23, 2018 (Filed With SEC on August 29, 2019)
- Lonza Sublicense Agreement, by and between the Registrant and MedImmune, LLC, dated as of February 23, 2018 (Filed With SEC on August 29, 2019)
- Asset Purchase Agreement, by and between the Registrant and MedImmune, LLC, MedImmune Limited and AstraZeneca Collaboration Ventures, LLC, dated as of February 23, 2018 (Filed With SEC on August 29, 2019)
- License Agreement, by and between the Registrant and MedImmune, LLC, dated as of February 23, 2018 (Filed With SEC on August 29, 2019)
- Clinical Supply Agreement, by and between the Registrant and AstraZeneca UK Limited, dated as of February 23, 2018 (Filed With SEC on August 29, 2019)
- Master Supply and Development Services Agreement, by and between the Registrant and AstraZeneca UK Limited, dated February 23, 2018 (Filed With SEC on August 29, 2019)
- Transition Services Agreement, by and between the Registrant and MedImmune, LLC, dated February 23, 2018 (Filed With SEC on August 29, 2019)
- Medical Research Council Payment Agreement, by and between the Registrant and MedImmune Limited, dated February 23, 2018 (Filed With SEC on August 29, 2019)
- Commercial Supply Agreement, by and between the Registrant and AstraZeneca Pharmaceuticals LP, dated as of April 4, 2019 (Filed With SEC on August 29, 2019)
- License and Collaboration Agreement, by and between the Registrant and Hansoh Pharmaceutical Group Company Limited, dated May 24, 2019 (Filed With SEC on August 29, 2019)
- Long-term Lease Agreement, by and between the Registrant and MedImmune, LLC, dated as of June 30, 2018 (Filed With SEC on August 29, 2019)
- Executive Severance Plan (Filed With SEC on August 29, 2019)
- Non-Employee Director Compensation Plan (Filed With SEC on August 29, 2019)
